In November the Food and Drug Administration (FDA) warned the direct-to-consumer gene testing company 23andMe to stop marketing its $99 genotype screening test. The FDA's letter gave 23andMe 15 days to respond, warning that if the agency didn't like what it heard, the potential results could "include, but are not limited to, seizure, injunction, and civil money penalties." Ronald Bailey says that despite the FDA's parade of horrible hypotheticals, the bigger risk is that increased regulation will slow down the progress of beneficial genetic testing and treatment.
Brett Kavanaugh Faces a New Accusation in The New York Times, but the Alleged Victim Didn't Confirm It
Plus: Andrew Yang opts out of cancel culture, Andrew Cuomo wants to crack down on flavored e-cigarettes, and more...
Kamala Harris Does Not Understand Why the Constitution Should Get in the Way of Her Gun Control Agenda
The presidential contender conspicuously fails to explain the legal basis for her plan to impose new restrictions by executive fiat.
Comedy, meet cancel culture
This is bending the Lanham Act until it nearly breaks